Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?

Documenti analoghi

• Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
  di: Fiorelli, Alfonso, et al.
  Pubblicazione: (2020)
• Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
  di: Shen, Peng, et al.
  Pubblicazione: (2018)
• Adjuvant TKI treatment of EGFR-mutant lung cancer—already ripe for decision?
  di: Kauffmann-Guerrero, Diego
  Pubblicazione: (2020)
• EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
  di: Wu, Jing-Xun, et al.
  Pubblicazione: (2018)
• Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance
  di: Luo, Yung-Hung, et al.
  Pubblicazione: (2014)